Corcept Therapeutics (NASDAQ:CORT): Q2 Non-GAAP EPS of $0.25 beats by $0.07; GAAP EPS of $0.17 misses by $0.01.
Revenue of $72.26M (+16.0% Y/Y) beats by $1.39M.
Shares +0.18%.
Thursday, August 1, 2019
Medifast EPS beats by $0.07, beats on revenue
Medifast (NYSE:MED): Q2 GAAP EPS of $1.75 beats by $0.07.
Revenue of $187.1M (+59.5% Y/Y) beats by $5.36M.
Intersect ENT, Inc. EPS misses by $0.03, misses on revenue
Intersect ENT, Inc. (NASDAQ:XENT): Q2 GAAP EPS of -$0.36 misses by $0.03.
Revenue of $26.66M (+1.4% Y/Y) misses by $0.47M.
Shares -0.84%.
Bio-Rad Labs EPS beats by $0.23, beats on revenue
Bio-Rad Labs (NYSE:BIO): Q2 Non-GAAP EPS of $1.57 beats by $0.23.
Revenue of $572.6M (-0.6% Y/Y) beats by $7.72M.
Twist Bioscience EPS misses by $0.11, beats on revenue
Twist Bioscience (NASDAQ:TWST): Q3 GAAP EPS of -$0.92 misses by $0.11.
Revenue of $13.6M (+108.0% Y/Y) beats by $0.85M.
Select Medical EPS in-line, misses on revenue
Select Medical (NYSE:SEM): Q2 GAAP EPS of $0.33 in-line.
Revenue of $1.36M (-99.9% Y/Y) misses by $1.34B.
BioMarin Q2 miss pressures shares, down 3% after hours
BioMarin Pharmaceutical (NASDAQ:BMRN) Q2 results ($M): Revenues: 387.8 (+4.0%).
Key product sales: Vimizim: 122.7 (-3.8%), Kuvan: 113.3 (+3.9%), Naglazyme: 98.2 (+7.8%), Palynziq: 18.8.
Net income: (37.4) (-122.6%); non-GAAP net income: 17.1 (-14.1%); EPS: (0.21) (-133.3%).
2019 guidance: Revenues: $1,680M – 1,750M; Vimizim: $530M – 570M; Kuvan: $420M – 460M; Naglazyme: $350M – 380M; Palynziq: $70M – 100M; net income: ($85M – 45M); non-GAAP net income: $130M – 170M (all unchanged).
Shares down 3% after hours.
Previously: BioMarin Pharmaceutical EPS misses by $0.09, misses on revenue (Aug. 1)
Subscribe to:
Posts (Atom)